Navigation Links
Knocking out survival protein could aid leukemia treatment

An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows.

The findings suggest that a drug that can block this "survival protein" might on its own be an effective therapy.

But such a drug used in combination with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly.

The survival protein is called Mcl1. It usually helps keep normal cells healthy and is involved in the development of the components of the immune system, but it can also help prolong survival of cancer cells.

Cells with an overabundance of the protein are also more resistant to anticancer drugs such as rituximab, which has revolutionized the treatment of certain chronic and acute leukemias.

The study by researchers at the Ohio State University Comprehensive Cancer Center is published online in the journal Clinical Cancer Research.

"Our findings demonstrate that Mcl1 may be an effective target for drugs directed against CLL and ALL," says principal investigator John C. Byrd, professor of internal medicine and director of the hematologic malignancies program at Ohio State's James Cancer Hospital and Solove Research Institute.

"These results give us a rationale for lowering the amount of this protein in CLL cells and suggest that this should enhance the action of rituximab and perhaps other agents as well."

Rituximab is an antibody-based drug that targets CLL and ALL cells and causes the cells to self-destruct.

"We've shown that knocking down Mcl1 can, by itself, cause CLL cells to die, and that this effect might enhance the activity of rituximab," says first author Rehan Hussain, a postdoctoral fellow with Ohio State's Comprehensive Cancer Center.

B yrd, Hussain and their collaborators conducted this research using cancer cells from 17 CLL patients and ALL cell lines grown in the laboratory.

The investigators placed molecules called small interfering RNA (siRNA) inside the cells and found that the tiny molecules greatly reduced the amount of the survival protein, causing many of the cells to die. The effect was the same even in cells that came from patients with advanced cancer or from patients with tumors that resisted conventional treatment.

When the researchers treated cells with both siRNA and the drug rituximab, the combination killed significantly more leukemia cells than the drug alone.

Overall, says Byrd, "Our data indicate that specifically targeting Mcl1 might be effective in the treatment of CLL, particularly when combined with rituximab."

Source:Ohio State University

Related biology news :

1. The Bacterias guide to survival
2. Boosting HIV screening can increase survival and is cost effective
3. Researchers identify protein crucial for survival of Lyme-disease bacterium
4. Novel protein complex enables survival in hostile environment
5. BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins
6. UCI researchers discover key factor for survival of human embryonic stem cells
7. Rhinos clinging to survival in the heart of Borneo, despite poaching
8. DNA: Bacterias survival ration
9. New research promising for improving brain cell survival after brain injury
10. AIDS vaccine research offers new insights on survival
11. New path from estrogen to survival in breast cancer cells described

Post Your Comments:

(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  The Minnesota High ... of the 2015 Tekne Award in the Small and ... at the Minneapolis Convention Center, ... played a significant role in developing new technologies that ... around the world. Clostridium difficile infection ...
(Date:12/1/2015)... ... December 01, 2015 , ... RURO, Inc., ... selling system laboratory animal colony management software solution, ezColony®, is now available as ... IT resources., , Many organizations are moving to cloud-hosting ...
(Date:12/1/2015)... Harry Lander , President of Regen, expands his role to ... and recruits five distinguished scientists to join advisory ... expands his role to include serving as ... scientists to join advisory team --> Dr. Harry Lander ... serving as Chief Science Officer and ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for the ... in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new ...
Breaking Biology Technology: